By Suherman Candra Maholtra 
In the wake of the global COVID-19 pandemic, the landscape of vaccinology underwent a paradigm shift, transitioning from traditional inactivated or viral vector methods to the rapid deployment of messenger RNA (mRNA) technology. While the first clinical administration of an mRNA vaccine on December 8, 2020, marked a historic milestone—subsequently estimated to have saved at least 14.4 million lives within its first year of global distribution—the limitations of this platform have become increasingly apparent. As the medical community grapples with the waning immunity and logistical hurdles associated with mRNA, a multidisciplinary team from the Wyss Institute at Harvard University, the Dana-Farber Cancer Institute (DFCI), and several partner institutions has unveiled a revolutionary alternative. This new platform, known as DoriVac, utilizes DNA origami nanotechnology to provide a more stable, precise, and easily manufactured vaccine chassis that could redefine the future of immunization against infectious diseases.
The Evolution of Vaccine Technology and the mRNA Bottleneck
The success of the Pfizer-BioNTech and Moderna vaccines proved that mRNA could be developed and scaled with unprecedented speed. However, as the SARS-CoV-2 virus continued to evolve into numerous variants—from Delta to the various Omicron sublineages—the limitations of the first-generation mRNA vaccines emerged. Research has shown that the immune protection generated by these vaccines varies significantly across different demographics and tends to diminish over time. Furthermore, the rapid mutation of the viral spike protein allows the virus to partially evade the neutralizing antibodies induced by current mRNA formulations, necessitating frequent booster shots and constant updates to the vaccine sequence.
Beyond biological limitations, the practical challenges of mRNA technology are significant. The manufacturing process is notoriously complex, involving the delicate packaging of mRNA molecules into lipid nanoparticles (LNPs). Controlling the exact ratio of mRNA to LNPs remains a technical hurdle that affects consistency. Perhaps most critically, the requirement for ultra-cold storage—often between -80°C and -20°C—creates a "cold-chain" dependency that limits vaccine accessibility in under-resourced regions and developing nations. These vulnerabilities have spurred a global search for a "Vaccine 2.0" that offers the same rapid development potential as mRNA but with enhanced stability and broader protective capabilities.
DoriVac: A Programmable Nanoscale Vaccine Platform
To address these challenges, researchers led by William Shih, Ph.D., and Yang (Claire) Zeng, M.D., Ph.D., turned to DNA origami. This field of nanotechnology involves the folding of DNA strands into specific, two- or three-dimensional shapes at the nanometer scale. The DoriVac platform (DNA origami vaccine) functions as a sophisticated delivery vehicle that integrates both the antigen (the part of the pathogen the immune system recognizes) and the adjuvant (a substance that enhances the immune response) into a single, programmable structure.
The DoriVac chassis is built from self-assembling DNA nanostructures, typically shaped like tiny squares or blocks. This level of structural precision allows scientists to control the exact spacing of molecules. On one side of the DNA structure, researchers can arrange adjuvant molecules at nanometer-scale distances to optimize the activation of immune cells. On the opposing side, they can attach specific antigens, such as peptides or proteins derived from viruses or tumors. This spatial organization mimics the way pathogens naturally present themselves to the immune system, leading to a more robust and targeted defensive response.
Targeted Immunity Through the HR2 Peptide
A key innovation in the DoriVac study, recently published in Nature Biomedical Engineering, is the targeting of the HR2 (Heptad Repeat 2) peptide region. Unlike the receptor-binding domain of the spike protein, which is highly prone to mutations, the HR2 region is relatively conserved across various strains of SARS-CoV-2 and is also found in other lethal viruses, including HIV and Ebola. By focusing on this "vulnerability" in the viral structure, the researchers aim to create a vaccine that provides broader protection against multiple variants and even different virus families.
In preclinical trials involving mice, the DoriVac SARS-CoV-2 HR2 vaccine demonstrated a remarkable ability to trigger both humoral (antibody-driven) and cellular (T cell-driven) immunity. The data indicated a significant increase in the production of B cells, which are responsible for long-term antibody production, and dendritic cells (DCs), which act as the "sentinels" of the immune system by presenting antigens to T cells.
Bridging the Gap: Human Organ-on-a-Chip Validation
One of the most persistent failures in vaccine development is the "translational gap"—the phenomenon where treatments that work in mice fail to produce the same results in humans. To circumvent this, the Wyss Institute team utilized their proprietary microfluidic human Organ Chip technology. Specifically, they employed a "human lymph node-on-a-chip" (human LN Chip) to simulate the human immune response in a controlled, in vitro environment.
The human LN Chip contains live human immune cells and replicates the physiological conditions found in a human lymph node, where immune responses are initiated. When the DoriVac vaccine was introduced to this system, it successfully activated human dendritic cells and induced a significant surge in inflammatory cytokines. Furthermore, the platform showed a marked increase in the population of CD4+ and CD8+ T cells—vital components for identifying and destroying infected cells. This successful simulation suggests that the results observed in animal models are highly likely to translate to human clinical success.
Head-to-Head: DoriVac vs. mRNA-LNP Vaccines
In a direct comparison that represents a significant milestone for nanotechnology, the research team evaluated the performance of DoriVac against the industry-standard mRNA lipid nanoparticle vaccines produced by Moderna and Pfizer/BioNTech. When both vaccines were configured to carry the full SARS-CoV-2 spike protein and administered as boosters in mice, the results were striking: DoriVac produced an immune response comparable in strength to the mRNA vaccines.
However, the advantages of DoriVac extend beyond its immunological potency. William Shih, a Wyss Institute Core Faculty member and Professor at Harvard Medical School, emphasized the platform’s superior stability. Unlike mRNA, which is highly unstable and prone to degradation, DNA origami structures are inherently more durable. DoriVac vaccines do not require the same stringent cold-chain infrastructure, potentially allowing them to be stored at room temperature or in standard refrigeration for extended periods. This makes DoriVac an ideal candidate for global distribution, particularly in tropical climates or regions with unreliable electricity.
Moreover, the manufacturing process for DNA origami is arguably more predictable than LNP formulation. Because the DNA strands self-assemble according to precise genetic sequences, the resulting vaccine particles are uniform in size and composition. This reduces the risk of unintended "off-target" effects and ensures a more consistent dose-to-dose profile.
Chronology and Strategic Development
The development of DoriVac has followed a strategic path from oncology to infectious diseases. In early 2024, Shih’s team introduced DoriVac as a cancer vaccine platform, demonstrating its ability to shrink tumors in mice by precisely delivering neoantigens to the immune system. As the COVID-19 pandemic persisted, the team, led by Dr. Yang (Claire) Zeng, pivoted to explore whether the platform’s "superior adjuvant activity" could be applied to viral threats.
Collaborating with Donald Ingber’s team at the Wyss Institute—specialists in AI-driven antiviral innovation—the researchers expanded the DoriVac portfolio to include targets for HIV and Ebola. This timeline illustrates the platform’s versatility; it is not merely a COVID-19 vaccine but a "chassis" that can be quickly reprogrammed to address any emerging pathogen or chronic infectious disease.
Professional Analysis and Future Implications
The implications of the DoriVac platform for global health are profound. By providing a vaccine that is as effective as mRNA but significantly more stable and easier to produce, the Wyss Institute and its partners are addressing the most critical weaknesses in current pandemic preparedness.
Dr. Donald Ingber, Director of the Wyss Institute and co-corresponding author, noted that the convergence of DNA nanotechnology and Organ-on-a-Chip testing creates a new paradigm for drug development. "This convergence of technologies enabled us to dramatically raise the chances of success for a new class of vaccines," Ingber stated. The ability to predict human immune responses before entering clinical trials could save years of development time and billions of dollars in research costs.
Furthermore, the focus on conserved antigens like the HR2 peptide suggests a move toward "universal" vaccines. If a single DoriVac formulation can protect against multiple variants of a virus, the need for seasonal updates could be greatly reduced, easing the burden on healthcare systems and improving public compliance with vaccination schedules.
As DoriNano—the startup founded by Dr. Zeng to commercialize this technology—moves toward clinical trials, the medical community will be watching closely. The initial safety profiles have been promising, and the flexibility of the DNA origami structure allows for the "plug-and-play" addition of different antigens as new threats emerge. While mRNA vaccines were the heroes of the 2020 pandemic, the next era of infectious disease defense may well be written in the precise, folded strands of DNA origami.
The research was supported by a diverse array of international bodies, including the National Institutes of Health (NIH), the Bill and Melinda Gates Foundation, and the National Research Foundation of Korea. This global support underscores the high stakes involved in developing a more equitable and robust vaccine infrastructure for the 21st century. Through DoriVac, the promise of nanotechnology is finally being realized in a way that could protect billions from the next great viral threat.
